Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
New Drug Application for INNOVENT BIO's Sintilimab Combination with HUTCHMED's Fruquintinib Accepted in CN
Recommend 13 Positive 15 Negative 11 |
||||
|
||||
|
HUTCHMED (00013.HK) and INNOVENT BIO (01801.HK) jointly announced that their new drug application for the combination therapy of fruquintinib and sintilimab has been accepted by China's National Medical Products Administration. This therapy is intended for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
